ArticleNPJ precision oncology2023

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance.

Mandy Sakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.